Ge Long Hui·2025-07-29 11:36Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of its self-developed drug "B019" for the treatment of refractory systemic lupus erythematosus [1] Group 1 - The clinical trial approval allows the company to advance its research on B019, which targets a significant unmet medical need in the treatment of systemic lupus erythematosus [1] - B019 is positioned as a potential innovative therapy in the biopharmaceutical sector, reflecting the company's commitment to developing new treatments [1] - The approval marks a critical milestone in the drug development process, potentially leading to future commercialization opportunities for the company [1]